Impact of Using Self-Assembling Peptide (PuraStat) on Anastomotic Ulcers—A Multicenter Case Series
Treatment of anastomotic ulcers, also known as marginal ulcers, is challenging, especially when established techniques have failed. PuraStat is a biocompatible synthetic peptide gel that is indicated for hemostasis of bleeding in the gastrointestinal tract and vascular anastomoses. We aim to evaluate the feasibility of PuraStat in the setting of nonhealing anastomotic ulcers when used alongside standard therapies. This is a multicenter case series of adult patients who had PuraStat applied with a follow-up repeat endoscopy. Nine out of 10 patients showed clinical improvement. We concluded that PuraStat is an effective agent to aid in healing of anastomotic ulcer.
Authors
- Yousef Fazel
- Mohit Girotra (ORCID: https://orcid.org/0000-0002-7086-7211)
- Nitish Mittal (ORCID: https://orcid.org/0000-0002-4934-3157)
- Harshit S. Khara (ORCID: https://orcid.org/0000-0003-2850-625X)
- Amar Manvar
- Shivangi Kothari (ORCID: https://orcid.org/0000-0002-6175-002X)
- Veeral M. Oza
- Adam Goodman (ORCID: https://orcid.org/0000-0002-3429-1067)
- Truptesh Kothari (ORCID: https://orcid.org/0000-0001-8244-1130)
- Charles Winchester
Institutions
- Geisinger Medical Center (US)
- Strong Memorial Hospital (US)
- Long Island University (US)
- University of Rochester Medical Center (US)
- Bon Secours Mercy Health (US)
- New York University (US)
- Washington State University (US)
- Georgia Highlands College (US)
Publication Details
- Journal
- ACG Case Reports Journal
- Published
- 2024-10-01
- DOI
- https://doi.org/10.14309/crj.0000000000001535
- Citations
- 3
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- Boston Scientific Corporation
- Castle Biosciences